S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80

Amneal Pharmaceuticals Stock Forecast, Price & News

-0.10 (-3.01%)
(As of 07/6/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
460,431 shs
Average Volume
689,068 shs
Market Capitalization
$975.42 million
P/E Ratio
Dividend Yield
Price Target

Amneal Pharmaceuticals MarketRank™ Forecast

Analyst Rating
0.00 Rating Score
117.4% Upside
$7.00 Price Target
Short Interest
4.57% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Proj. Earnings Growth
From $0.80 to $0.81 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.90 out of 5 stars

Medical Sector

595th out of 1,433 stocks

Pharmaceutical Preparations Industry

288th out of 683 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Amneal Pharmaceuticals logo

About Amneal Pharmaceuticals (NYSE:AMRX) Stock

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

AMRX Stock News Headlines

Amneal Pharmaceuticals (NYSE:AMRX) Trading Up 6.6%
Amneal Pharmaceuticals (NYSE:AMRX) Trading 9.4% Higher
Amneal Pharmaceuticals (NYSE:AMRX) Shares Up 9.4%
Recap: Amneal Pharmaceuticals Q4 Earnings
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
0 Analysts


Net Income
$91.06 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.99 billion
Cash Flow
$0.99 per share
Book Value
$1.15 per share


Free Float
Market Cap
$975.42 million

Amneal Pharmaceuticals Frequently Asked Questions

What is Amneal Pharmaceuticals' stock price forecast for 2022?

0 equities research analysts have issued 12-month price objectives for Amneal Pharmaceuticals' shares. Their AMRX stock forecasts range from $7.00 to $7.00. On average, they predict Amneal Pharmaceuticals' share price to reach $7.00 in the next year. This suggests a possible upside of 117.4% from the stock's current price.
View analysts' price targets for Amneal Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Amneal Pharmaceuticals' stock price performed in 2022?

Amneal Pharmaceuticals' stock was trading at $4.79 at the beginning of the year. Since then, AMRX stock has decreased by 32.8% and is now trading at $3.22.
View the best growth stocks for 2022 here

When is Amneal Pharmaceuticals' next earnings date?

Amneal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Amneal Pharmaceuticals

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) released its quarterly earnings results on Wednesday, May, 4th. The company reported $0.10 EPS for the quarter, hitting the consensus estimate of $0.10. The business earned $497.30 million during the quarter, compared to the consensus estimate of $502.29 million. Amneal Pharmaceuticals had a net margin of 0.68% and a trailing twelve-month return on equity of 61.08%. The company's quarterly revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.19 EPS.
View Amneal Pharmaceuticals' earnings history

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of $0.80-$0.85 for the period, compared to the consensus estimate of $0.84. The company issued revenue guidance of $2.15 billion-$2.25 billion, compared to the consensus revenue estimate of $2.19 billion.

Who are Amneal Pharmaceuticals' key executives?

Amneal Pharmaceuticals' management team includes the following people:
  • Mr. Chirag K. Patel, Co-Founder, Co-CEO, Pres & Director (Age 55, Pay $1.52M) (LinkedIn Profile)
  • Mr. Chintu Patel R.Ph, R.Ph., Co-Founder, Co-CEO & Director (Age 50, Pay $1.53M)
  • Mr. Anastasios G. Konidaris, Exec. VP & CFO (Age 55, Pay $893.24k)
  • Ms. Nikita Shah, Exec. VP and Chief HR & Strategic Planning Officer (Age 44, Pay $807.09k) (LinkedIn Profile)
  • Mr. Andrew S. Boyer, Exec. VP & Chief Commercial Officer of Generics (Age 56, Pay $1.1M)
  • Mr. Anthony DiMeo, Sr. Director of Investor Relations
  • Mr. Jason B. Daly Esq., Sr. VP, Chief Legal Officer & Corp. Sec. (Age 48)
  • Mr. Sanjiv Patel, Sr. VP of Operations
  • Dr. Nikunj Patel, Head of Ops & Exec. VP of Amneal Pharmaceuticals (India) Pvt Ltd
  • Mr. Sanjay Kumar Jain Ph.D., Pres of India Operations

What is Chirag and Chintu Patel's approval rating as Amneal Pharmaceuticals' CEO?

23 employees have rated Amneal Pharmaceuticals CEO Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among Amneal Pharmaceuticals' employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $3.22.

How much money does Amneal Pharmaceuticals make?

Amneal Pharmaceuticals (NYSE:AMRX) has a market capitalization of $975.42 million and generates $1.99 billion in revenue each year. The company earns $91.06 million in net income (profit) each year or $0.09 on an earnings per share basis.

How many employees does Amneal Pharmaceuticals have?

Amneal Pharmaceuticals employs 7,000 workers across the globe.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The official website for Amneal Pharmaceuticals is www.amneal.com. The company can be reached via phone at (908) 947-3120, via email at invest@amneal.com, or via fax at 908-947-3146.

This page (NYSE:AMRX) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.